https://www.thebodypro.com/category/fda-approved-hiv-medications

FDA-Approved HIV Medications

The Latest

Could an Integrase Inhibitor Have Prevented One More HIV Infection? Img

Could an Integrase Inhibitor Have Prevented One More HIV Infection?

Monica Gomes, M.D., M.Sc. presents a case where perhaps adding an integrase inhibitor during pregnancy may have helped prevent one more instance of mother-to-child transmission.

Promo Image
Metabolic

Long-Term Exposure to Protease Inhibitors May Increase Diabetes Risk in HIV

This article was reported by Healio.

Healio reported on a study of the effect of long-term exposure to antiretrovirals (ARVs) and increased diabetes risk in HIV-positive individuals. Researchers conducted a retrospective observational study using 19...

Promo Image

Attachment Inhibitor Shows Some Progress in Trials

Programs that have sought to develop anti-HIV drugs (of all classes) have sometimes produced candidate compounds that may appear potent in laboratory experiments with cells. However, when these compounds are later tested in people, they sometimes fai...

Kaposi's Sarcoma and HIV: Not Gone, Not Forgotten Img
Cancer

Kaposi's Sarcoma and HIV: Not Gone, Not Forgotten

Think Kaposi's sarcoma is a relic of a bygone era? A flurry of new research highlights just how relevant the disease still is -- and how much about it we have yet to learn.

Viral Load Rebound Rate of 35% Using Ritonavir-Boosted PI Monotherapy: Results of 5-Year PIVOT Study Img
Conference Coverage

Viral Load Rebound Rate of 35% Using Ritonavir-Boosted PI Monotherapy: Results of 5-Year PIVOT Study

A long-term strategy study sponsored by the Medical Research Council (MRC) in the UK reported low rates of serious complications and the potential to reduce drug costs. However, more than a third of people on the ritonavir-boosted PI monotherapy grou...

Promo Image
Conference Coverage

NNRTI Resistance Found in 12% of People Stopping Treatment With Undetectable Viral Load: Implications for Stock-Outs

Although stopping ART is not recommended, this still occurs due to drug stock-outs in some countries and retrospective data from the UK HIV Drug Resistance Database (HDRD) highlighted the risk this has for developing drug resistance.

Valentina Cambi...

Promo Image
Conference Coverage

Switching to Stribild From Non-Nuke or Protease Inhibitor Regimens Works Well

So with all the positive news about integrase inhibitors in initial HIV treatment, is it safe to switch patients from other NNRTI (non-nucleoside reverse transcriptase inhibitor)- or PI (protease inhibitor)-based regimens to integrase inhibitor regim...

Promo Image
Conference Coverage

Raltegravir Superior to Boosted Protease Inhibitors as First-Line Treatment

U.S. treatment guidelines equally recommend first-line treatment regimens that include either a non-nucleoside reverse transcriptase inhibitor (NNRTI), efavirenz (Sustiva, Stocrin); one of two ritonavir (Norvir)-boosted protease inhibitors (PIs), ata...

5 ID/HIV Things to Be Grateful for This Holiday Season Img
Viewpoints

5 ID/HIV Things to Be Grateful for This Holiday Season

I was speaking with a British colleague the other day, and she was remarking how jealous she was that we get a Thanksgiving holiday each year. Starting with a long whine (or moan, as they would say) about the pressures, commercialization, cost, and r...

Lipids Respond Well to Switch From Boosted PI to Rilpivirine/Tenofovir/Emtricitabine (Complera), Study Finds Img
News

Lipids Respond Well to Switch From Boosted PI to Rilpivirine/Tenofovir/Emtricitabine (Complera), Study Finds

Many people who had high lipid levels while taking common HIV treatment regimens that included a protease inhibitor, such as Prezista or Reyataz, saw remarkable improvements after the switch.